Digest Network Come funziona
Network
/
Società
Za
Non verificato

Zai Lab Limited

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza

55 comunicati stampa

Guarda tutti i comunicati
23/12/2025
Industria
Psichiatria
Salute
Farmaceutica
Medicina - Varie
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
08/12/2025
Industria
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Sanità
Salute
Oncologia
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
07/12/2025
Industria
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Farmaceutica
Biotecnologia
Zai Lab Announces Updates to China’s National Reimbursement Drug List
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
06/11/2025
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Farmaceutica
Biotecnologia
Web e Social Network
Telefonia e Varie
Mercato azionario
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
31/10/2025
Biotecnologia
Salute
Sanità
Farmaceutica
Oncologia
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Eventi
Fiere
Zai Lab Announces Participation in Investor Conferences in November and December 2025
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
24/10/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Web e Social Network
Telefonia e Varie
Eventi
Industria
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
15/10/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
13/10/2025
Sanità
Scienza
Farmaceutica
Oncologia
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Salute
Web e Social Network
Telefonia e Varie
Eventi
Industria
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
02/09/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Industria
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
28/08/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Eventi
Web e Social Network
Zai Lab Announces Participation in Investor Conferences in September 2025
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0